These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27467318)

  • 1. The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy.
    Lang BH; Shek TW; Wan KY
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):236-242. PubMed ID: 27467318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features.
    Lang BH; Wong CKH
    Ann Surg Oncol; 2016 Oct; 23(11):3641-3652. PubMed ID: 27221359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of High-Risk Characteristics Requiring Total Thyroidectomy for 1-4 cm Well-Differentiated Thyroid Cancer.
    Kluijfhout WP; Pasternak JD; Lim J; Kwon JS; Vriens MR; Clark OH; Shen WT; Gosnell JE; Suh I; Duh QY
    Thyroid; 2016 Jun; 26(6):820-4. PubMed ID: 27083216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.
    Rosario PW; Mourão GF; Calsolari MR
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):453-8. PubMed ID: 26801644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study.
    Kuba S; Yamanouchi K; Hayashida N; Maeda S; Adachi T; Sakimura C; Kawakami F; Yano H; Matsumoto M; Otsubo R; Sato S; Fujioka H; Kuroki T; Nagayasu T; Eguchi S
    Int J Surg; 2017 Feb; 38():143-148. PubMed ID: 27677707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
    Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
    Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative ultrasonographic features of papillary thyroid carcinoma predict biological behavior.
    Nam SY; Shin JH; Han BK; Ko EY; Ko ES; Hahn SY; Chung JH
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1476-82. PubMed ID: 23463652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
    Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
    J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.
    Adam MA; Pura J; Gu L; Dinan MA; Tyler DS; Reed SD; Scheri R; Roman SA; Sosa JA
    Ann Surg; 2014 Oct; 260(4):601-5; discussion 605-7. PubMed ID: 25203876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome.
    Radowsky JS; Howard RS; Burch HB; Stojadinovic A
    Thyroid; 2014 Feb; 24(2):241-4. PubMed ID: 23713855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?
    Kiernan CM; Parikh AA; Parks LL; Solórzano CC
    J Am Coll Surg; 2015 Apr; 220(4):617-25. PubMed ID: 25667136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients.
    Craig SJ; Bysice AM; Nakoneshny SC; Pasieka JL; Chandarana SP
    Thyroid; 2020 Feb; 30(2):222-228. PubMed ID: 31813323
    [No Abstract]   [Full Text] [Related]  

  • 16. Individualizing Surgery in Papillary Thyroid Carcinoma Based on a Detailed Sonographic Assessment of Extrathyroidal Extension.
    Kuo EJ; Thi WJ; Zheng F; Zanocco KA; Livhits MJ; Yeh MW
    Thyroid; 2017 Dec; 27(12):1544-1549. PubMed ID: 29113553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of microscopic extra-nodal extension (ENE) on locoregional recurrence following curative surgery for papillary thyroid carcinoma.
    Lang BH; Shek TW; Wan KY
    J Surg Oncol; 2016 Apr; 113(5):526-31. PubMed ID: 26792294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.